



Advanced Anticonvulsant System **AAS**

Description

The Advanced Anticonvulsant System (AAS) will treat seizures and prevent subsequent neurological damage caused by exposure to nerve agents. The AAS, injected intramuscularly, will consist of the drug midazolam in an autoinjector. Midazolam will replace diazepam in the fielded Convulsant Antidote for Nerve Agents (CANA). Midazolam is more water-soluble than diazepam and terminates nerve agent-induced seizures more quickly than diazepam. AAS will not eliminate the need for other protective and therapeutic systems. U.S. Food and Drug Administration approval is planned for 2QFY2014.



Mission

Provide protection against nerve agent-induced seizures and subsequent neurologic damage.

-Target Capability: Protect against nerve agent-induced seizures and subsequent neurological damage when used with fielded therapeutic systems (atropine and 2-PAM)

-Target Capability: Prevent reoccurrence of seizures

-Improvements over the CANA: Faster acting and more effective

Capabilities

- Chemical Therapeutics

Users

US Navy, US Marine Corps, US Army, US Air Force

Status

Engineering and Manufacturing Development - Anticipated Fielding: FY 2014 Q3

This Fact Sheet was cleared for public release on 1/22/2013.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@us.army.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919